Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 999 of 6351
-
Could less radiation be safer for tough lung tumors?
Disease control Recruiting nowThe purpose of this trial is to test a deescalated 3-fraction stereotactic body radiotherapy (SBRT) regimen to 45 Gray (Gy) in 3 fractions for centrally located thoracic tumors.
Phase 1/2 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy aims to boost immune attack on brain cancer
Disease control OngoingPatients with newly diagnosed glioblastoma will be consented following tumor resection then undergo leukapheresis for harvest of peripheral blood leukocytes for generation of dendritic cells. Subjects will then receive standard of care (planned 6 weeks) radiation therapy (RT) and…
Phase 2 • Sponsor: Annick Desjardins, MD • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New combo offers CLL patients a chance for drug-free holidays
Disease control OngoingThis phase II trial investigates the how well acalabrutinib and obinutuzumab work in treating patients with chronic lymphocytic leukemia (CLL). Acalabrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with obinutuzumab…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Which IV fluid is safer for kids with sepsis? major trial gives answers
Disease control CompletedThe objectives of this multicenter pragmatic clinical trial are to compare the effectiveness and relative safety of balanced fluid resuscitation versus 0.9% "normal" saline in children with septic shock, including whether balanced fluid resuscitation can reduce progression of kid…
Phase 3 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Robots vs cameras: which surgery wins for lung cancer?
Disease control Recruiting nowVideo-assisted thoracic surgery (VATS) has been recommended by clinical guidelines as one of the preferred surgeries for early-stage non-small cell lung cancer (NSCLC) for many years. However, VATS has inherent drawbacks, so at the beginning of this century, robotic-assisted thor…
Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Heavy ion beam offers new hope for tough Head-and-Neck cancers
Disease control Recruiting nowAfter multimodal therapy of head-and-neck tumors, patients often develop local recurrence, locally progressive disease or second primary tumors. In this highly pre-treated patient cohort, therapeutic options are limited. Patients that are not candidates for salvage surgery may be…
Sponsor: University Hospital Heidelberg • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Can early TNF blockers stop arthritis drugs for good?
Disease control OngoingThe SPARTACUS study will explore the therapeutic efficacy of 2 different treatment strategies for patients suffering from peripheral Spondyloarthritis (pSpA), classified according to the "Assessment in SpondyloArthritis international Society" (ASAS) classification criteria; it wi…
Phase 3 • Sponsor: University Hospital, Ghent • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Could immature sperm cells help infertile men become fathers?
Disease control Recruiting nowThe purpose of this research study is to evaluate if special types of cells called round spermatids can be gathered from men with non-obstructive azoospermia and used (in absence of elongated spermatids and spermatozoa) to reliably and effectively create pregnancy with a procedur…
Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New hope for rare cancers: drug combo trial launches
Disease control Recruiting nowBackground: People with rare cancers often have limited treatment options. The biology of rare cancers is not well understood. Researchers want to find better treatments for these cancers. They want to test 2 drugs that, taken separately, have helped people with non-rare cancers…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 09, 2026 15:00 UTC
-
Could a targeted drug boost survival in Hard-to-Treat lymphoma?
Disease control OngoingParticipants in this study will have diffuse large B-cell lymphoma (DLBCL) that has come back or not gotten better with treatment. The trial will study whether brentuximab vedotin plus two drugs works better to treat this type of cancer than the two drugs alone. Participants wil…
Phase 3 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Milder chemo before stem cell transplant shows promise for rare blood disorders
Disease control Recruiting nowThis is a data collection study that will examine the general diagnostic and treatment data associated with the reduced-intensity chemotherapy-based regimen paired with simple alemtuzumab dosing strata designed to prevented graft failure and to aid in immune reconstitution follow…
Sponsor: Paul Szabolcs • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Could a new drug combo beat elephantiasis?
Disease control CompletedThe purpose of this study is to determine whether moxidectin (Mox) will be more effective than ivermectin (IVM) when used in single-dose combination therapies for lymphatic filariasis (LF).
Phase 3 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug shows promise for tough hodgkin lymphoma cases
Disease control CompletedThis was a Phase 2 trial evaluating the effectiveness and safety of tislelizumab in participants with relapsed or hard-to-treat classical Hodgkin lymphoma (cHL). Participants were grouped by prior treatments. The main outcome was to assess overall response rate (ORR) across both …
Phase 2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New shot shows promise against tough lymphoma in japanese study
Disease control OngoingThe trial is an open-label, multi-center safety and preliminary efficacy trial of epcoritamab (EPKINLY™) in Japanese participants with relapsed, progressive or refractory B-cell lymphomas and Japanese participants with B-cell lymphomas that have achieved partial response (PR) or …
Phase 1/2 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 09, 2026 15:00 UTC
-
Could donor bacteria beat recurring vaginal infections?
Disease control OngoingVaginal Microbiome Transplantation (VMT) may be beneficial in treating the most severe cases of recurrent and antibiotics-nonresponsive cases of BV. Recently, we completed a preliminary study in which we treated patients with recurrent and antibiotics-non-responsive, intractable …
Phase 1/2 • Sponsor: Hadassah Medical Organization • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Could a testosterone boost help fight resistant prostate cancer?
Disease control Recruiting nowAsymptomatic men without pain due to prostate cancer progressing with metastatic CRPC after treatment with combination or sequential ADT + Abi will be treated on a randomized, open label study to determine if sequential treatment with high dose T and Enza will improve primary and…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New combo aims to stop prostate cancer relapse after surgery
Disease control CompletedMain Study: The purpose of main study is to assess if the combination of apalutamide and androgen deprivation therapy (ADT) in participants with high-risk localized prostate cancer improves the biochemical recurrence (BCR) free rate. Sub-study: The purpose of the sub-study is to…
Phase 2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Targeted drug combo shows promise for chinese lung cancer patients with BRAF mutation
Disease control CompletedThis was a single-arm, open label, multicenter phase II, study of dabrafenib in combination with trametinib in Chinese participants with BRAF V600E mutation positive, stage IV NSCLC (American joint committee on cancer staging 8th edition). Approximately 40 Chinese adults were to …
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Supercharged immune cells take on post-transplant viruses
Disease control OngoingThe purpose of this research study is to learn more about the use of viral specific T-lymphocytes (VSTs) to treat viral infections that may happen after solid organ transplant (SOT). VSTs are cells specially designed to fight viral infections that may happen after a solid organ t…
Phase 2 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New radioactive drug shows promise for tough prostate cancer
Disease control OngoingThe purpose of the initial (phase I) portion of this study is to find a dose level and administration schedule of the study drug, 225Ac-J591, that can be given without severe side effects. The purpose of the second (phase II) portion of the study is to determine the proportion of…
Phase 1 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC